Compare CPOP & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPOP | ATRA |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.4M | 38.9M |
| IPO Year | 2020 | 2014 |
| Metric | CPOP | ATRA |
|---|---|---|
| Price | $0.31 | $4.84 |
| Analyst Decision | | Sell |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | ★ 258.0K | 56.8K |
| Earning Date | 11-17-2025 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 122.52 |
| EPS | N/A | ★ 2.57 |
| Revenue | N/A | ★ $120,772,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $1.91 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.28 | $3.92 |
| 52 Week High | $2.60 | $19.15 |
| Indicator | CPOP | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 49.20 | 47.21 |
| Support Level | $0.30 | $4.22 |
| Resistance Level | $0.36 | $5.47 |
| Average True Range (ATR) | 0.04 | 0.33 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 35.58 | 33.59 |
Pop Culture Group Co Ltd hosts entertainment events, operates hip-hop-related online programs, and provides event planning and execution services and marketing services to corporate clients. It generates revenue from Event Hosting business by providing sponsorship packages to advertisers in exchange for sponsorship fees and by selling tickets for those concerts. The company has various operations services out of which Brand Promotion earns maximum revenue, following by Event Hosting, and Event Planning and Execution.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).